IGCLBSEIndogulf Cropsciences LtdMediumNeutral
Announced Thu, 28 May · 19:10 IST

Earnings Call Presentation of the Company pertaining to Q4 of FY 2025-26

Investor Communications View source PDF

IGCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-6.2%1-day move
₹62.90
prior close
₹64.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.6-1.6-3.0-6.6-6.2-7.9-7.8-9.3-9.9-5.4-2.2-4.3
Up moveDown movePending
AI summary

Indogulf Cropsciences reported strong FY26 results with revenue of INR 7,046 million (up 19% YoY) and PAT of INR 400 million (up 27% YoY). Q4 FY26 revenue was INR 1,506 million (up 19% YoY) with PAT of INR 116 million. Gross margins improved to 31% in FY26 from 29.8% in FY25, indicating better product mix. However, EBITDA margins declined to 10.4% from 10.9% due to higher employee and other expenses growing faster than revenue. The company has 4 manufacturing facilities with 52% capacity utilization and is expanding the Barwasni facility for dry flowable products. Revenue mix is heavily skewed towards Crop Protection (85%) with Biologicals at 6% and Plant Nutrients at 5%. The company operates across B2C (50%), B2B (38%), and Exports (11%) channels.

Likely market impact

The 19% revenue growth with 27% PAT growth shows improving operational efficiency and cost management. Gross margin improvement indicates successful focus on high-value products, though slight EBITDA margin compression may concern cost-sensitive investors. The company's expansion into biologicals and new export markets like Venezuela and Brazil provides growth visibility.